MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update MapLight Therapeutics (Nasdaq: MPLT) reported Q4 and full‑year 2025 results and a clinical update on March 26, 2026. Cash, cash equivalents and investments were $453.1 million at year‑end, expected to fund operations through 2027. Key clinical milestones: Phase 2 ZEPHYR (schizophrenia) enrollment expected April 2026 (n=300) with topline results in Q3 2026; IRIS (ML‑004 for ASD) enrollment complete with topline in Q3 2026; VISTA (ADP) topline expected H2 2027; FDA Fast Track granted for ML‑007C‑MA in ADP. R&D and G&A expenses and net loss rose in 2025 versus 2024 due largely to clinical, CMC and IPO‑related stock compensation costs.

#MPLT MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MPLT/map-light-ther...

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s

#MPLT MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

www.stocktitan.net/news/MPLT/map-light-ther...

MapLight Therapeutics’ ML-007C/MA Earns FDA Fast Track Designation for Alzheimer’s Disease Psychosis MapLight Therapeutics (Nasdaq: MPLT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational therap

#MPLT
MapLight Therapeutics’ ML-007C/MA Earns FDA Fast Track Designation for Alzheimer’s Disease Psychosis
prismmarketview.com/maplight-the...

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 /M 4 muscarinic agonist, for the

#MPLT MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

www.stocktitan.net/news/MPLT/map-light-ther...

SandboxAQ and MapLight Therapeutics Partner to Develop AI-Discovered First-in-Class CNS Therapies SandboxAQ and MapLight Therapeutics (Nasdaq: MPLT) have entered into a strategic collaboration aimed at discovering and developing potential first-in-class ther

SandboxAQ teams up with MapLight Therapeutics (Nasdaq: #MPLT) in a deal worth up to $200M to use AI and molecular simulation to discover first-in-class therapies for CNS disorders.
prismmarketview.com/sandboxaq-an...

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled

#MPLT SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

www.stocktitan.net/news/MPLT/sandbox-aq-and...

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress MapLight Therapeutics (Nasdaq: MPLT) reported third quarter 2025 results and program milestones on Dec 4, 2025. Key clinical timelines: ZEPHYR Phase 2 topline for ML-007C-MA in schizophrenia expected in H2 2026; VISTA Phase 2 topline for Alzheimer’s disease psychosis expected in H2 2027; IRIS Phase 2 topline for ML-004 in ASD expected in H2 2026. The company completed enrollment in IRIS (~160 participants) and nominated ML-009 for IND-enabling studies; ML-021 IND-enabling studies expected complete H2 2026. Financing: completed an IPO and private placement in Oct 2025 raising $296.5 million gross ($269.8 million net). Cash, cash equivalents and short-term investments were $227.2 million at quarter end, expected to fund operations through 2027.

#MPLT MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

www.stocktitan.net/news/MPLT/map-light-ther...

Just finished an amazing season with these talented musicians, #MarchingPrideofLawrenceTownship ( #MPLT ) . Got thousands of images & video from their performances. Looking forward to editing their end-of-season video!

#MarchingBand #MarchingBandPhotography #PerformancePhotography #CaptureTheMoment